Analyst Thomas Shrader of BTIG maintained a Buy rating on NRX Pharmaceuticals (NRXP – Research Report), retaining the price target of $18.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Thomas Shrader has given his Buy rating due to a combination of factors that highlight NRX Pharmaceuticals’ potential for growth and innovation. The company is making significant strides in developing its HOPE network, which is set to become a unique platform with access to differentiated drugs pending FDA approval. This network is expected to generate substantial revenue, aligning with management’s guidance for future financial performance.
Additionally, NRX Pharmaceuticals is advancing its drug pipeline with promising candidates like NRX-100 and NRX-101, which are moving toward potential approvals. The recent patent filing for NRX-100, which could protect the drug until 2045, adds another layer of value by securing intellectual property rights. The company’s financial position, supported by cash reserves and strategic partnerships, further strengthens its outlook, making it an attractive investment opportunity.
According to TipRanks, Shrader is an analyst with an average return of -1.0% and a 33.40% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Novavax, Coya Therapeutics, Inc., and Arcturus Therapeutics.